Table 1.

In-trial cost-effectiveness results

Outcomes	Enalapril-folic acid (n = 10348)	Enalapril (n = 10354)	∆ (Enalapril-folic acid–Enalapril) (95%CI)	P value
Enalapril/enalapril-folic acid cost ($/￥)	$1170.46 ￥7549.47	$137.41 ￥886.29	$1033.05 (1029.51 to 1036.59) ￥6663.18 (6640.35 to 6686.01)	< 0.001
Concomitant drug cost ($/￥)	$75.13 ￥484.60	$73.01 ￥470.91	$2.12 (− 2.20 to 6.44) ￥13.69 (− 14.16 to 41.54)	0.335
Stroke-related costs ($/￥)
Ischemic stroke	$32.95 ￥212.55	$43.13 ￥278 .16	$− 10.17 (− 16.66 to − 3.68) ￥− 65.61 (− 107.45 to − 23.76)	0.002
Hemorrhagic stroke	$17.98 ￥115.96	$19.21 ￥123.88	$− 1.23 (− 7.86 to 5.41) ￥− 7.93 (− 50.72 to 34.87)	0.717
Other CVD-related costs ($/￥)	$10.89 ￥70.25	$9.98 ￥64.36	$0.91 (− 5.11 to 6.94) ￥5.89 (− 32.97 to 44.75)	0.766
Total costs ($/￥)	$923.74 ￥5958.14	$217.71 ￥1404.22	$706.03 (695.28 to 716.79) ￥4553.92 (4484.56 to 4623.27)	< 0.001
QALY	3.92	3.90	0.016 (− 0.001 to 0.033)	0.064
ICER ($/QALY)/(￥/QALY)	$44,127.13 ￥284,620

QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio